HEAD-TO-HEAD STUDY SHOWS ORAL FERRIC MALTOL (FERACCRU®) MAY BE AN ALTERNATIVE TREATMENT TO INTRAVENOUS (IV) FERRIC IRON, OFFERING A REAL ALTERNATIVE OPTION TO HOSPITAL ADMINISTRATION FOR PATIENTS WITH IRON DEFICIENCY ANAEMIA (IDA) AND INACTIVE INFLAMMATORY BOWEL DISEASE (IBD)
22 October 2019
CORPORATE MEDIA RELEASE
NORGINE MARKS 50TH ANNIVERSARY OF PHARMACEUTICAL MANUFACTURING SITE IN WALES
AMSTERDAM, The Netherlands, 10th June 2019, 11.15 AM CET / 10:15 AM BST.
Norgine, a leading European specialist pharmaceutical company, celebrated the 50th anniversary of its manufacturing site in Hengoed, Wales on Friday 7th June. The event marked the achievements of Norgine’s Hengoed staff along with our global network of partners who have dedicated themselves to bringing life-changing medicines to millions of patients worldwide.
Norgine is one of the largest pharmaceutical employers in Wales. Since opening its doors in 1969, Norgine’s Hengoed site has grown from 50 employees to over 370 permanent staff today, many of whom have worked there for over 25 years.
Every year Norgine helps around 23 million patients worldwide. Hengoed contributes annually over 30 million packs of medicines, which help people living with constipation and support the diagnosis and prevention of serious gastro-intestinal diseases such as colorectal cancer. Norgine is committed to manufacturing excellence and has invested nearly £13 million in the site in the last five years alone to enable the production of high-quality, life-improving medicines.
Peter Stein, Chairman and Chief Executive Officer of Norgine spoke during the event and commented, “We are extremely proud of the work carried out at our site in Hengoed. Today is about celebrating the contribution that each member of staff has made to improving the lives of patients all over the world over the past 50 years.”
Councillor Julian Simmonds, Mayor of Caerphilly Borough Council commented, “I am delighted to have joined Norgine in celebrating their successful and longstanding commitment to Hengoed. The company has brought a great deal to Caerphilly’s economy and its positive reputation amongst locals reflects Norgine’s investment in its employees.”
Wayne David MP (Member of Parliament for Caerphilly) added, “It’s amazing to think that medicines created in Hengoed help people in so many countries around the world. Wales has a lot to offer the life sciences sector and it’s great to see that a company like Norgine has played such an important role in our community for the past 50 years.”
Dr Hefin David AM (Assembly Member for Caerphilly) also highlighted, “Norgine has been an important employer in the Rhymney Valley for half a century. They are well-established at Tir-y-Berth Industrial Estate and provide high-skilled, well-paid jobs in a vital and growing industry. I am confident that Norgine will continue to have a significant presence locally and I look forward to working with them in the years ahead.”
Founded in 1906, Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century.
For further information or an interview with Wayne David MP, Dr Hefin David AM or Peter Stein, CEO of Norgine, please contact:
Eleni Fistikaki +44 (0)1895826227 or +44 (0)7825 389477
Clara Bentham +44 (0)1895 826654 or +44 (0)7734 367883
Follow us @norgine
Notes to editors:
Norgine has a direct presence in 14 European countries, Australia and New Zealand as well as a strong global network of partnerships in non-Norgine markets.
The Norgine B.V. group is a fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients.
Norgine employs over 1,300 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sales and supply.
In 2012, Norgine established a complementary business, Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe. For more information, please visit www.norgineventures.com
NORGINE and the sail logo are trademarks of the Norgine group of companies.
About Norgine’s manufacturing site in Hengoed
Norgine has been researching and manufacturing innovative medicines in Hengoed since 1969 to improve the lives of millions of patients around the world. Manufacturing takes place 24 hours a day, 7 days a week to supply over 30 million packs of medicines around the world every year. Norgine’s Hengoed site has won an RoSPA gold award for their approach to health and safety for the last five years in a row. In 2015, the company opened a new £4.5 million temperature-controlled warehouse in Hengoed, and since 2014, has spent nearly £14,500 on training grants. We are proud to be one of the largest pharmaceutical employers in Wales.
The Hengoed site is the place of employment for a number of families, including the Lewis family, in this picture with Peter Stein, CEO of Norgine (third from left). Sharon Lewis began working at Hengoed in 2001, and is now joined by her daughters Janine and Joanne, who have both been working at Hengoed for the past 15 years, her son David, who has been working at Hengoed for the past 14 months and their aunt Lesley Davey.